



Platinum[®] World Portfolios PLC Quarterly Investment Manager's Report

Platinum World Portfolios - Health Sciences Fund

31 March 2023

 **Platinum[®]**
WORLD PORTFOLIOS PLC

Contents

Performance Returns	3
Fund Updates	
PWP - Health Sciences Fund	4

Performance

to 31 March 2023

SUB-FUND	PORTFOLIO VALUE (US\$ MIL)	QTR	1 YR	2 YRS COMPOUND PA	3 YRS COMPOUND PA	5 YRS COMPOUND PA	SINCE INCEPTION COMPOUND PA	INCEPTION DATE
PWP - Health Sciences Fund								
Class D (USD)	24.9	-1.7%	-	-	-	-	-	28 Oct 2022

Fund returns are net of accrued fees and expenses, are pre-tax, and assume the accumulation of net income and capital gains. Where a particular share class is not denominated in USD, the net asset value per share in USD, being the Fund's base currency, is converted into the denomination currency of that share class using the prevailing spot rate.

Historical performance is not a reliable indicator of future performance. Returns could be reduced, or losses incurred due to currency fluctuations See note 1, page 9.

Source: Platinum Investment Management Limited for Fund returns; FactSet Research Systems for MSCI Index returns.

Platinum Health Sciences Fund



Dr Bianca Ogden
Portfolio Manager

Performance

(to 31 March 2023)

SHARE CLASS	QUARTER	SINCE INCEPTION
PWP Health Sciences Fund Class D USD	-2%	1%

Fund returns are net of accrued fees and costs. Inception date is 28 Oct 2022.
The Fund uses an absolute return hurdle for performance comparison purposes and for the purposes of calculating performance fees payable to the investment manager. Source: Platinum Investment Management Limited.

Historical performance is not a reliable indicator of future performance. Returns could be reduced, or losses incurred due to currency fluctuations. See notes 1 & 2, page 9.


The Fund (Class D) returned -1.7% for the quarter.¹

The global healthcare sector had the worst start to the year in 30 years relative to the S&P 500 index (see Fig. 1).

The PWP - Health Sciences Fund primarily invests in companies that develop new therapies, devices or diagnostic approaches. The Fund also focuses on companies that enable such innovations to take place, such as next-generation tools used by scientists. For the past 18 months or so, these subsectors of healthcare have been abandoned by generalist investors due to the changing interest rate environment. Many companies in this subsector are unprofitable and depend on external capital, which is now more difficult to come by. In the past six months, we have witnessed a glimpse of a recovery, but the collapse of Silicon Valley Bank, which has been a crucial provider of

¹ References to returns and performance contributions (excluding individual stock returns) in this PWP - Health Sciences Fund report are in USD terms, unless otherwise specified. Individual stock and index returns are quoted in local currency terms and sourced from FactSet Research Systems, unless otherwise specified.

Fig. 1: Healthcare Performance Relative to S&P 500 Calendar Year to Date (US\$)



Source: Goldman Sachs Global Investment Research, FactSet Research Systems.

As at the date of this document there is insufficient data for the Value of US\$100,000 Invested Chart.

funding to many start-ups in this space, has again put a dampener on the recovery. In all honesty, the biotech sector is currently priced as if it is going out of business.

A recent chart from Goldman Sachs highlights the fact that valuations of biotech companies are currently at rock-bottom levels (see Fig. 2). These levels have historically coincided with recessions and, most importantly, have marked key inflection points for the sector.


For further context, the SPDR S&P Biotech ETF (XBI), an index that largely comprises non-profitable biotechs, returned -8.2% in US dollar terms for the quarter. As mentioned, the Fund returned -1.7% for the quarter.

Pharmaceutical (pharma) companies have held up relatively better, reflecting their attraction as safe havens. The pharma companies that we own focus on retooling, including **Takeda Pharmaceutical** and **Sanofi**. Both companies are making good progress and have provided a positive contribution to the Fund's performance over the quarter, rising 6% and 12%, respectively. A special mention goes to Sanofi, which received new drug approvals and promising data in chronic obstructive pulmonary disease (COPD) for its key anti-inflammatory antibody, Dupixent.

Other contributors to performance over the quarter included US biotech **Albireo Pharma** (+103%), which was acquired by French biopharmaceutical company Ipsen over the quarter. Albireo's focus is on bile-acid modulators to treat rare liver conditions and complements Ipsen's rare disease portfolio. **Bayer** (+21%) rallied after further chatter on a potential breakup and the appointment of Bill Anderson as the new CEO. Bill was previously the CEO of Roche Pharma and is considered to be a very pragmatic manager. This is yet another member of the Roche alumni taking on the task of reforming a company with a drug discovery engine problem.

Key detractors over the quarter included **Icosavax**, **Alector** and **Quanterix**, which all weakened in line with the biotech sector. **Redx Pharma** (-52%) was another significant underperformer, with the stock weakening following its unsuccessful reverse merger with a US biotech.

Fig. 2: Biotech Enterprise Value (EV)/Sales



Source: Goldman Sachs Global Investment Research, FactSet Research Systems.

Disposition of Assets

REGION	31 MAR 2023	31 DEC 2022
North America	33%	29%
Europe	18%	19%
Japan	4%	5%
Asia	3%	4%
Australia	2%	0%
Cash	39%	43%

See note 4, page 9. Numerical figures have been subject to rounding.
Source: Platinum Investment Management Limited.

Net Sector Exposures

SECTOR	31 MAR 2023	31 DEC 2022
Biotechnology	32%	28%
Pharmaceuticals	22%	23%
Life Sciences Tools & Services	5%	5%
Other	2%	1%
TOTAL NET EXPOSURE	61%	57%

See note 5, page 9. Numerical figures have been subject to rounding.
Source: Platinum Investment Management Limited.

Net Currency Exposures

CURRENCY	31 MAR 2023	31 DEC 2022
United States Dollar (USD)	72%	69%
Euro (EUR)	13%	17%
Japanese Yen (JPY)	4%	5%
Chinese Renminbi (CNY)	3%	4%
UK Pound Sterling (GBP)	3%	3%
Australian Dollar (AUD)	2%	0%
Danish Krone (DKK)	1%	1%
Swedish Krona (SEK)	1%	1%

See note 6, page 9. Numerical figures have been subject to rounding.
Source: Platinum Investment Management Limited.

Changes to the Portfolio

Since the inception of the Fund on 28 October 2022, we have continued to deploy capital into a range of names. Given the company-level volatility that this sector experiences, often exacerbated by events early in the year, we continue to apply our disciplined approach to valuations while looking for opportune times to invest further in a prudent fashion.

We initiated a new position in **Esperion Therapeutics** during the quarter, and we added to various investments that, despite their good progress, continue to see an ongoing lack of investor interest. One such example is **Exscientia**; it announced two new pipeline assets moving into the clinic during the quarter, but its valuation is again back below an enterprise value of US\$50 million, as many investors are waiting for clinical data. We added to our position as we see a productive drug discovery engine in the making. We also added to **Icosavax**, **Omega Therapeutics** and **Zealand Pharma**. At the same time, we trimmed some of our holdings, which had a great start to the year, including **Albireo Pharma** (exited), **Takeda** and **Zai Lab**.

Commentary

Pharma companies are sitting on very healthy balance sheets, but so far, they have not deployed very much of it. Life for pharma companies is not going to get any easier, given that a patent cliff is approaching towards the end of this decade and price pressure is set to intensify as a result of the Inflation Reduction Act provisioning for Medicare to negotiate certain prescription drugs starting in 2026. Mergers and acquisitions (M&A) are inevitable given that the competitive dynamics of the industry have changed significantly over the past two decades. Today, a market monopoly for a new mechanism of action drug is no longer a given; peers, as well as biotech companies, are fast followers, continuously adding pressure. Hence, the days of being able to take your time and tinker with a new R&D project are behind us; today, the need to increase R&D efficiency is paramount.

Product portfolio concentration is also an issue for pharma companies, with often one product contributing significantly to sales. Fig. 3 summarises the concentration of the top product as a percentage of sales at pharma companies.

Merck stands out, with Keytruda (sales of US\$21 billion in 2022) accounting for more than half of its pharma sales. While Keytruda is approved for many cancer indications, it is still striking to see how concentrated Merck's product portfolio has become. Merck's pipeline does have some interesting assets coming through, such as sotatercept for pulmonary hypertension (obtained via its acquisition of Acceleron, which was held in the Fund at the time), an oral peptide inhibitor of PCSK9, a key enzyme that regulates cholesterol (UCB, a holding in the Fund, will receive royalties

Fig. 3: Top Product as a % of Pharma Sales (2022)

COMPANY	% OF PHARMA SALES*	BRAND NAME	MECHANISM OF ACTION	DISEASE INDICATION	PHARMA SALES % OF OVERALL BUSINESS SALES
Merck	54.9	Keytruda	anti-PD1	Oncology	71%
Abbvie	36.6	Humira	anti-TNF	Inflammatory disease	100%
Sanofi	27.0	Dupixent	anti-IL4/13	Inflammatory disease	71%
Eli Lilly	26.1	Trulicity	GLP-1 agonist	Metabolic disease	100%
BMJ	25.5	Eliquis	anti-Fxa	Cardiovascular disease	100%
GSK	24.2	Dolutegravir	Integrase Inhibitor	HIV infection	73%
JNJ	19.3	Stelara	anti-IL12/23	Inflammatory disease	65% after spin-off of consumer division
Pfizer	17.7	Eliquis	anti-Fxa	Cardiovascular disease	85%
AstraZeneca	13.5	Tagrisso	anti-EGFR	Lung cancer	100%
Roche	13.3	Ocrevus	anti-CD20	Multiple Sclerosis	70%
Novartis	11.6	Cosentyx	anti-IL17A	Inflammatory disease	100% following spin-off of Sandoz division

Source: Company reports, Platinum Investment Management Limited.

*Pharma sales are defined as pure pharma, excluding vaccine, consumer and animal health sales. For Merck and Pfizer, COVID-related sales are also excluded.

for this product upon approval), as well as personalised cancer vaccines from Moderna, but overall, diversification is paramount for Merck. Not that long ago, Merck was seen as a contender to buy antibody biotech Seagen, however, during the quarter, Pfizer was the successful bidder, acquiring Seagen for US\$40 billion (2023E sales of US\$2.2 billion). Pfizer estimates the acquisition will generate US\$10 billion in sales by 2030.²

Keytruda's US patent expires in 2028, with Merck working on a subcutaneous injectable version as well as coformulations with other immuno-oncology pipeline products. The company will see cash accumulate on its balance sheet leading into 2028; hence, we are likely to see more acquisitions. Post quarter-end, on 17 April, Merck did indeed announce the acquisition of Prometheus Biosciences for US\$10.8 billion, a company held in the Fund that we discussed in the December 2022 quarterly report.³ Merck will pay US\$200 per share for the company, which represents a 75% premium to the previous day's closing price.⁴

Today, pharma companies need to focus on externally sourced R&D just as much as their internal R&D projects. Their venture capital arms will play a key role in helping to engage with the biotech industry, as will the alumni networks of these large companies. Biotechs are the innovators in the healthcare sector, a fact that was further highlighted in the recent IQVIA Institute report, *Global Trends in R&D 2023*. The data shows that emerging biopharma companies⁵ are the ones that "are responsible for two-thirds of the R&D pipeline".⁶

Outlook

Many investors in the healthcare sector are trying to figure out where to hide, and during the March quarter, the defensive nature of healthcare did not really play out. M&A is not a fix; it is part of life in this sector. The Silicon Valley Bank collapse was unhelpful and has put the biotech sector back to square one, with funding becoming an issue and a buyer's strike happening again. We will be paying close attention to clinical data as well as approval decisions for several of our holdings.

Top 10 Holdings

COMPANY	COUNTRY	INDUSTRY	WEIGHT
Takeda Pharmaceutical	Japan	Health Care	3.9%
Bayer AG	Germany	Health Care	3.8%
Sanofi SA	US	Health Care	3.5%
Exscientia Plc	UK	Health Care	2.4%
Gilead Sciences Inc	US	Health Care	2.2%
Galapagos NV	Belgium	Health Care	2.2%
UCB SA	Belgium	Health Care	2.2%
Quanterix Corp	US	Health Care	1.9%
Telix Pharmaceuticals Ltd	Australia	Health Care	1.9%
Icosavax Inc	US	Health Care	1.8%

As at 31 March 2023. See note 7, page 9.

Source: Platinum Investment Management Limited.

For further details of the Fund's invested positions, including country and industry breakdowns and currency exposures, updated monthly, please visit www.platinumworldportfolios.ie/The-Funds/PWP-Health-Sciences-Fund

2 Source: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer>

3 https://www.platinumworldportfolios.ie/PlatinumSite/media/Updates-Reports/Health%20Sciences/ptwhqtr_1222.pdf

4 Source: <https://www.reuters.com/markets/deals/merck-late-stage-talks-acquire-prometheus-biosciences-wsj-2023-04-16/>

5 Companies that spend less than US\$200 million a year on R&D and have less than US\$500 million in sales.

6 Source: <https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023>

Disclaimers: This publication was prepared by Platinum Investment Management Limited (ABN 25 063 565 006) (AFSL 221935), trading as Platinum Asset Management (Platinum), as the Investment Manager for, and on behalf of, Platinum World Portfolios PLC (the "Company"), an open-ended investment company with variable capital incorporated with limited liability in Ireland with registered number 546481 and established as an umbrella fund with segregated liability between sub-funds pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended. Platinum World Portfolios - International Fund, Platinum World Portfolios - Asia Fund, Platinum World Portfolios - Japan Fund and Platinum World Portfolios - Health Sciences Fund (each a "Fund", as the context requires, and together the "Funds") are sub-funds of the Company.

This is a marketing communication. This is not a contractually binding document. Prior to making any investment in the Company, please refer to the Company's prospectus and to the relevant key investor information document ("KIID") and do not base any final investment decision on this communication alone. This publication has been approved by Mirabella Advisers LLP. Platinum UK Asset Management Limited (Company No. 11572258) is an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority - number 606792. Platinum UK Asset Management Limited is a subsidiary of Platinum and the appointed sub-distributor of the Company in the United Kingdom.

This publication contains general information only and is not intended to provide any person with investment advice. Acquiring shares in the Company may expose an investor to a significant risk of losing all of the amount invested. The Company is a limited liability company and any person who acquires shares in the Company will not thereby be exposed to any significant risk of incurring additional liability. Any person should consider their own financial position, objectives and requirements and seek professional advice before making any financial decisions. Any person should also read the prospectus before making any decision to acquire shares in the Company. The prospectus and KIIDs, which further detail the risks relating to investment in the Company, can be obtained online at www.platinumworldportfolios.ie.

Neither the Company nor any company in the Platinum Group, including any of their directors, officers or employees (collectively "Platinum Persons"), guarantee the performance of any of the Funds, the repayment of capital, or the payment of income. Past performance is not a reliable indicator of future performance. Returns could be reduced, or losses incurred, due to currency fluctuations. The Platinum Group means Platinum Asset Management Limited ABN 13 050 064 287 and all of its subsidiaries and associated entities (including Platinum). To the extent permitted by law, no liability is accepted by any Platinum Person for any loss or damage as a result of any reliance on this information. This publication reflects Platinum's views and beliefs at the time of preparation, which are subject to change without notice. No representations or warranties are made by any Platinum Person as to their accuracy or reliability. This publication may contain forward-looking statements regarding Platinum's intent, beliefs or current expectations with respect to market conditions. Readers are cautioned not to place undue reliance on these forward-looking statements. No Platinum Person undertakes any obligation to revise any such forward-looking statements to reflect events and circumstances after the date hereof.

This publication is aimed solely at professional clients within the meaning of Article 4.1(10) of the Markets in Financial Services Directive 2014/65/EU (MiFID II) ("Relevant Persons"). This document is an informational document and does not constitute an offer or invitation to subscribe for shares in the Company or in any other product or fund referenced herein, and no person other than a Relevant Person should act or rely on this presentation.

This Quarterly Report includes hyperlinks to other sites created and maintained by other public and/or private sector organisations. Platinum Asset Management UK provides these links solely for your information and convenience. When you link to an outside website, you are leaving this our Quarterly Report and our information management policies no longer apply.

Additional information for Qualified Investors in Switzerland

This is an advertising document. The state of the origin of the Company is Ireland. In Switzerland, this document may only be provided to qualified investors within the meaning of art. 10 para. 3 and 3ter CISA. In Switzerland, the representative is ACOLIN Fund Services AG, Leutschenbachstrasse 50, 8050 Zürich, Switzerland, whilst the paying agent is Helvetische Bank AG, Seefeldstrasse 215, 8008 Zürich, Switzerland. The basic documents of the Company as well as the annual and, if applicable, semi-annual report may be obtained free of charge from the representative. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Please be aware that this document may include funds for which neither a representative nor a paying agent in Switzerland have been appointed. These funds cannot be offered in Switzerland to qualified investors as defined in art. 5 para 1 FinSA.

Platinum World Portfolios PLC 2023. All rights reserved.

Notes: Unless otherwise specified, all references to "Platinum" in this report are references to Platinum Investment Management Limited (ABN 25 063 565 006, AFSL 221935). Some numerical figures in this publication have been subject to rounding adjustments. References to individual stock or index performance are in local currency terms, unless otherwise specified.

1. Fund returns are calculated by Platinum using the Fund's net asset value per share (i.e. excluding the anti-dilution levy) attributable to the specified share class. Where a share class is not denominated in USD, the net asset value per share in USD, being the Fund's base currency, is converted into the denomination currency of that share class using the prevailing spot rate. Fund returns are net of fees and expenses, pre-tax, and assume the accumulation of the net income and capital gains, each as attributable to the specified share class. The MSCI index returns are in USD, are inclusive of net official dividends, but do not reflect fees or expenses. MSCI index returns are sourced from FactSet Research Systems. Platinum does not invest by reference to the weightings of the specified MSCI index. As a result, the Fund's holdings may vary considerably to the make-up of the specified MSCI index. MSCI index returns are provided as a reference only. The investment returns shown are historical and no warranty is given for future performance. Historical performance is not a reliable indicator of future performance. Returns could be reduced, or losses incurred due to currency fluctuations. Due to the volatility in the Fund's underlying assets and other risk factors associated with investing, investment returns can be negative, particularly in the short term.
2. The portfolio inception dates for each active share class of the Fund are as follows:
 - Platinum World Portfolios - Health Sciences Fund
 - Class D USD (Accumulating) (ISIN: E0000SJFC91):
28 October 2022

For the purpose of calculating the "since inception" returns of the MSCI index, the inception date of Class D of the Fund is used (as Class D was the first share class activated).

3. The investment returns depicted in this graph are cumulative on US\$100,000 invested in Class D of the specified Fund over the specified period relative to the specified net MSCI Index in US Dollars.
4. The geographic disposition of assets (i.e. other than "cash" and "shorts") shows the Fund's exposures to the relevant countries/regions through its long securities positions and long securities/index derivative positions, as a percentage of its portfolio market value. Country classifications for securities reflect Bloomberg's "country of risk" designations. "Shorts" show the Fund's exposure to its short securities positions and short securities/index derivative positions, as a percentage of its portfolio market value. "Cash" in this table includes cash at bank, cash payables and receivables and cash exposures through long derivative transactions.
5. The table shows the Fund's net exposures to the relevant sectors through its long and short securities positions and long and short securities/index derivative positions, as a percentage of its portfolio market value. Index positions (whether through ETFs or derivatives) are only included under the relevant sector if they are sector specific, otherwise they are included under "Other".
6. The table shows the Fund's net exposures to the relevant currencies through its long and short securities positions, cash at bank, cash payables and receivables, currency forwards and long and short securities/index derivative positions, as a percentage of its portfolio market value. Currency classifications for securities reflect the relevant local currencies of the relevant Bloomberg country classifications. The

table may not exhaustively list all of the Fund's currency exposures and may omit some minor exposures.

7. The table shows the Fund's top ten positions as a percentage of its portfolio market value taking into account its long securities positions and long securities derivative positions.

MSCI Inc. Disclaimer: The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com)



PLATINUM WORLD PORTFOLIOS PUBLIC LIMITED COMPANY

An umbrella fund with segregated liability between sub-funds
Company Registration Number: 546481

BOARD OF DIRECTORS

Stephen Menzies (Australian)
Tony McPoland
Kevin Molony

REGISTERED OFFICE

Arthur Cox Building
Earlsfort Terrace
Dublin 2
Ireland

WEBSITE

www.platinumworldportfolios.ie



INVESTMENT MANAGER

Platinum Investment Management Limited
Level 8, 7 Macquarie Place
Sydney NSW 2000
Australia

GPO Box 2724
Sydney NSW 2001
Australia

TELEPHONE

+61 2 9255 7500

EMAIL

invest@platinum.com.au

LONDON OFFICE

Platinum UK Asset Management
20 North Audley Street
London, W1K 6LX
United Kingdom

TELEPHONE

+44 203 981 7898

EMAIL

tim.maher@platinumam.co.uk